Recent court decisions in Skinny Label cases show that liability increasingly focuses on post-launch conduct and real-world use, not label text alone. A panel of leading in-house counsel and litigators with innovative, biosimilar, and regulatory perspectives will address shifting litigation strategy.

• How branded and biosimilar companies should align legal, regulatory, and commercial behaviour.
• Analyse GSK v. Teva (Coreg) and the evidentiary role of marketing materials, sales conduct, and physician messaging.
• Discuss the original ruling in Amarin Pharma v. Hikma (Fed. Cir. 2024) , and examine the significance of Supreme Court review.
• Clarify evolving boundaries of permissible conduct for medical affairs, market access, and commercial teams.
• Compare with decisions made in other key jurisdictions including Canada and Europe.

Trade secret disputes increasingly involve conduct, data, and teams outside the U.S. In-house teams are finding that trade secret theft that appears “foreign” can still trigger U.S. litigation, while non-US data, employment, and disclosure rules can significantly limit how companies investigate and respond. Recent court decisions have clarified that the DTSA can reach conduct abroad, materially increasing exposure for global organisations. This session focuses on what extraterritorial trade secret risk looks like in practice and how in-house teams do ityou are adjusting their strategies.

• How the DTSA’s extraterritorial provisions under 18 U.S.C. § 1837 are being applied in practice.
• Lessons from Motorola Solutions v. Hytera (7th Cir. 2024), where U.S. courts allowed DTSA claims tied to foreign conduct and worldwide sales.
• How data protection laws, data localisation, and local employment rules affect investigations and discovery outside the U.S.
• Practical steps companies are taking to manage trade secret risk across global teams, systems, and vendors.
• Review recent cases to learn how companies have successfull

This session brings together senior in-house patent litigators involved in some of the most influential recent pharma and biotech cases, to examine how life sciences litigation strategy is shifting and what in-house teams should be preparing for next.

• Review key cases and court decisions from the past year, and what they reveal about where pharma and biotech patent litigation is evolving.
• How PTAB procedural developments are changing risk assessment, sequencing, and settlement strategy.
• Review venue selection within the US and consider when long-arm litigation can create leverage.

A concise review of recent US trade secret decisions that are shaping how courts assess reasonable measures, access, and remedies. This session brings together judges from key US jurisdictions to discuss the evolving expectations and outcomes from the most influential recent trade secret cases.